EUCTR2018-004330-15-FR进行中（未招募）1 期
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma - CONFIRM
Assistance Publique - Hôpitaux de Paris (AP-HP)0 个研究点目标入组 434 人开始时间: 2018年12月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 434
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1/ Adult patients (= 18 years old)
- •2/ Documented MM in relapse according to standard criteria and requiring initiation of a first line salvage therapy.
- •3/ Subject must have received one prior line of therapy for MM.
- •4/ Subject must have achieved a response (PR or better) to the prior regimen.
- •5/ Subject must have an ECOG Performance Status score of 0, 1, or 2.
- •6/ For subjects experiencing serious toxicities resulting from previous therapy (including peripheral neuropathy), the toxicities must have been resolved or stabilized.
- •7/ Signed informed consent
- •8/ Affiliation to a social security system or equivalent (recipient or assign)
- •9/ Effective method of contraception for the duration of treatment and 3 months after the last dose for women and men with a partner of childbearing age:
- •Progestin-only pill associated with inhibition of ovulation
- •Hormonal methods of contraception, including oral contraceptive pills containing a combination of estrogen + progesterone, vaginal ring, injectables, implants and intrauterine devices (IUDs)
- •non-hormonal IUD
- •Bilateral tubal occlusion
- •Vasectomized partner with documented azoospermia 90 days after procedure and who received a medical assessment of surgical success
- •Intrauterine hormone release system (IUS)
- •Complete Abstinence: Complete abstinence is defined as the complete avoidance of heterosexual intercourse. Complete abstinence is an acceptable form of contraception for all study drugs and must be used throughout the duration of the study and for the duration of time as specified above. It is not necessary to use any other method of contraception when complete abstinence is elected. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 284
排除标准
- •1/ Evidence of refractoriness or intolerance to lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody). If previously treated with a lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody) -containing regimen, the subject is excluded if he or she:
- •Discontinued due to any severe adverse event related to prior lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody) treatment, or
- •If, at any time point, the subject was refractory to any dose of lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody). Refractoriness to lenalidomide and/or daratumumab is defined either as:
- •oSubjects whose disease progressed within 60 days of lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody) administration; or
- •oSubjects whose disease is nonresponsive while on lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody). Nonresponsive disease is defined as either failure to achieve at least a minimal response or development of progressive disease while on lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody).
- •2/ Subject has received an allogenic stem cell transplant (regardless of timing).
- •3/ Subjects planning to undergo a stem cell transplant prior to progression of disease on this study, ie, these subjects should not be enrolled in order to reduce disease burden prior to transplant.
- •4/ Subject has a history of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence within 3 years).
- •5/ Subject has known MM meningeal involvement.
- •6/ Subject has plasma cell leukemia (>2.0 × 109/L circulating plasma cells by standard differential) or Waldenström’s macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis.
- •7/ Subject has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures or results, or that, in the opinion, of the investigator would constitute a hazard for participating in this study.
- •8/ Subject has known uncontrolled chronic obstructive pulmonary disease (COPD)
- •9/ Subject has clinically significant cardiac disease.
- •10/ Subject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
- •11/ Creatinine clearance =30 mL/min (MDRD method) (lenalidomide dose adjustment will be considered for subjects with creatinine clearance 30-60 mL/min).
- •12/ Hypersensitivity to the active substance or to any of the excipients
研究者
相似试验
进行中（未招募）
1 期
A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab (Treatment Beyond Progression, TBP). - GBG26/TBPEUCTR2005-002084-85-GBGBG Forschungs GmbH482
进行中（未招募）
1 期
A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancerEUCTR2008-006801-17-CZF. Hoffmann-La Roche Ltd.450
进行中（未招募）
1 期
A study of a combination of Trastuzumab and Capecitabine with or without Pertuzumab in patients with HER2-positive metastatic breast cancerHER2 positive metastatic breast cancer which has progressed after one line of trastuzumab-based therapy in the metastatic settingMedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006801-17-DEF. Hoffmann-La Roche Ltd.450
已完成
3 期
A multicenter randomized phase III study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting (PHEREXA)10006291breast cancerNL-OMON41586Covance4
进行中（未招募）
不适用
A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab (Treatment Beyond Progression) - GBG 26/TBPPatients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumabMedDRA version: 7.1Level: LLTClassification code 10027475EUCTR2005-002084-85-DKGBG Forschungs GmbH482